Biological treatment in elderly and young patients with ankylosing spondylitis: TURKBIO real-life data results
Authors:
- Ayşe CefleACAyşe Cefle
- Fatoş ÖnenFÖFatoş Önen
- Nurullah AkkoçNANurullah Akkoç
- Merih BirlikMBMerih Birlik
- İsmail SarıİSİsmail Sarı
- Özgül Soysal GündüzÖGÖzgül Soysal Gündüz
- Sema YılmazSYSema Yılmaz
- Servet YolbaşSYServet Yolbaş
- Aydan Köken AvşarAAAydan Köken Avşar
- Sadettin UsluSUSadettin Uslu
- Nevsun İnAnçNINevsun İnAnç
- Servet AkarSAServet Akar
Open Access
- 30 June 2024
- journal article
- research article
- Published by AVES YAYINCILIK A.Ş. in Archives of Rheumatology
- Vol. 39 (2) , 232-241
Abstract
Objectives: This study aims to investigate the effect of age on disease activity and biological treatment in patients with ankylosing spondylitis (AS). Patients and methods: A total of 811 AS patients registered in the TURKBIO registry database between 2011 and 2019 were categorized according to their age at the time of entry into the registry and assigned to one of two groups: young patients, defined asKeywords
This publication has 44 references indexed in Scilit:
- Prevalence of axial spondyloarthritis in PolandRheumatology International, 2019
- Profiling Response to Tumor Necrosis Factor Inhibitor Treatment in Axial SpondyloarthritisArthritis Care & Research, 2018
- Safety and Efficacy of Biological Disease-Modifying Antirheumatic Drugs in Older Rheumatoid Arthritis Patients: Staying the DistanceDrugs & Aging, 2016
- Rheumatoid Arthritis in the Elderly in the Era of Tight ControlDrugs & Aging, 2013
- Epidemiology of Spondyloarthritis: A ReviewCurrent Rheumatology Reports, 2013
- Performance of response scales of activity and functional measures of ankylosing spondylitis: numerical rating scale versus visual analog scaleRheumatology International, 2013
- Description of the registry of patients with ankylosing spondylitis in Turkey: TRASD-IPRheumatology International, 2010
- Cancer risk in patients with rheumatoid arthritis treated with anti–tumor necrosis factor α therapies: Does the risk change with the time since start of treatment?Arthritis & Rheumatism, 2009
- Efficacy and Safety of Anti-Tumour Necrosis Factor in Elderly Patients with Rheumatoid Arthritis: An Observational StudyClinical Reviews in Allergy & Immunology, 2009
- Tumor necrosis factor-α antagonist use and heart failure in elderly patients with rheumatoid arthritisAmerican Heart Journal, 2008